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Abstract
The objective of this work is to compare the adherence to
therapy of patients receiving etanercept and infliximab during
first tumour necrosis factor (TNF)-blocking treatment course in
rheumatoid arthritis. Special emphasis is placed on potential
predictors for treatment termination and the impact of
concomitant methotrexate (MTX) or other disease-modifying
antirheumatic drugs (DMARDs). Patients (n = 1,161) with active
rheumatoid arthritis, not responding to at least two DMARDs
including MTX starting etanercept or infliximab therapy for the
first time, were included in a structured clinical follow-up
protocol. Information on diagnosis, disease duration, previous
and ongoing DMARDs, treatment start and termination, as well
as cause of withdrawal was prospectively collected during the
period of March 1999 through December 2004. Patients were
divided into six groups according to TNF-blocking drugs and
concomitant DMARDs. Five-year level (one-year) of adherence
to therapy was 36% (69%) for patients receiving infliximab in
combination with MTX compared with 65% (89%) for patients
treated with etanercept and MTX (p < 0.001). Cox regression
models showed that the risk for premature treatment termination
of patients treated with infliximab was threefold higher than for
etanercept (p < 0.001). Also, the regression analysis showed
that patients receiving concomitant MTX had better treatment
continuation than patients treated solely with TNF blockers (p <
0.001). Moreover, patients receiving concomitant MTX had
superior drug survival than patients receiving other concomitant
DMARDs (p  < 0.010). The superior effect of MTX was
associated primarily with fewer treatment terminations because
of adverse events. In addition, the study identifies low C-reactive
protein level, high age, elevated health assessment
questionnaire score, and higher previous number of DMARDs
as predictors of premature treatment termination. In summary,
treatment with etanercept has higher adherence to therapy than
treatment with infliximab. Concomitant MTX is associated with
improved treatment continuation of biologics when compared
with both TNF blockers as monotherapy and TNF blockers
combined with other DMARDs.
Introduction
During the past decade, the armamentarium of effective
antirheumatic drugs has increased considerably. Neverthe-
less, a definite remission-inducing drug has yet to be discov-
ered, and the vast majority of rheumatoid arthritis (RA) patients
are dependent on lifelong treatment in order to suppress joint
damage and functional impairment. The efficacy and tolerabil-
ity of tumour necrosis factor (TNF) blockers have so far been
studied in randomised controlled clinical trials (RCTs) and
observational studies [1-10]. However, data directly compar-
ing different anti-TNF treatments and disease-modifying
antirheumatic drug (DMARD) combinations are still sparse.
This paper reports six-year data from an observational study
using a structured clinical protocol developed by the South
Swedish Arthritis Treatment Group (SSATG) [11]. The objec-
tive is to investigate predictors associated with premature
TNF-blocker treatment termination. Thus, we compare the
adherence to therapy of etanercept and infliximab in biologic-
naïve RA patients treated in clinical practice. Emphasis is
AE = adverse event; CI = confidence interval; CRP = C-reactive protein; DAS28 = 28-joint disease activity score; DMARD = disease-modifying 
antirheumatic drug; HAQ = health assessment questionnaire; HR = hazard ratio; MTX = methotrexate; RA = rheumatoid arthritis; RCT = randomised 
controlled trial; SSATG = South Swedish Arthritis Treatment Group; TNF = tumour necrosis factor; VASglobal = visual analogue scale for general 
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placed on the impact of concomitant methotrexate (MTX) or
other DMARDs and patient characteristics at treatment
initiation.
Materials and methods
Patients
Data were collected in a database following a structured clin-
ical protocol designed for drug monitoring. As the protocol
was designed to meet the legislative documentation required
in Sweden, no formal approval from the ethical committee was
necessary. Patients eligible for the study had a diagnosis of
RA according to clinical judgement by the treating physician.
A review showed that 98% of the patients fulfilled the Ameri-
can College of Rheumatology 1987 classification criteria for
RA. The patients were treated at eight hospital centers in
southern Sweden serving a population of about 1.3 million
during the period of March 1999 through December 2004.
During the entire study period, patients were continually
enrolled. A review of anti-TNF drugs sold in pharmacies com-
pared with patients registered in our database revealed that
approximately 90% of the patients receiving these drugs in
southern Sweden were included in the database [12]. Sub-
jects eligible for TNF-blocking therapy were selected by physi-
cians based on disease activity and/or unacceptable steroid
use. No formal level of disease activity was required; however,
the patients should have received at least two DMARDs,
including MTX previously without satisfactory response.
Selection of a particular drug was based primarily on availabil-
ity. The access to infliximab was limited in 1999, whereas sup-
ply of etanercept was limited during the period of February
2000 through June 2003 (Figure 1). Patients having received
biologic therapy prior to inclusion were excluded from this
study. Thus, only patients receiving their first treatment course
of biologic therapy (biologic-naïve patients) were enrolled in
the analysis.
Treatment guidelines encouraged infliximab to be adminis-
tered in combination with MTX. However, when infliximab was
introduced in Sweden, it was not obvious that co-medication
with MTX was needed and that is why a substantial number of
our infliximab patients were treated without concomitant MTX.
Dosages of the TNF-blocking agents followed the recommen-
dations of the manufacturers. Etanercept 25 mg subcutane-
ously was administered twice a week. Infliximab was infused at
3 mg/kg at 0, 2, and 6 weeks and then every eighth week.
Depending on primary or secondary failure, the dosage of inf-
liximab could be increased in increments of 100 mg to a max-
imum of 500 mg administered at 4- to 8-week intervals.
Method
Clinical data were prospectively collected at 0, 3, 6, and 12
months and subsequently every 3 to 6 months. No patients
were excluded for lack of registrations at any follow-up times.
At inclusion, the following data were recorded: year of disease
onset, previous and concomitant DMARD treatment, and sys-
temic prednisolone dosage. At inclusion and at each follow-up
visit, the following clinical data were registered: health assess-
ment questionnaire (HAQ) score, patient-scored visual ana-
logue scale for pain (VASpain) and general health
(VASglobal), physician's global assessment of disease activity
on a five-grade scale (EVALglobal), 28 tender and swollen
joint count, erythrocyte sedimentation rate, and C-reactive pro-
tein (CRP). The 28-joint disease activity score (DAS28) was
also calculated [13].
Any withdrawal from treatment was registered prospectively
and classified by the treating physician as withdrawal caused
by adverse events (AEs), lack of response/treatment failure, or
miscellaneous. No formal criteria were required to terminate
treatment, and the decision was based on the judgement of
the treating physician. The category 'miscellaneous' consisted
mainly of patients with poor compliance or subjects moving
away from southern Sweden. In approximately 2% of the with-
drawal cases, the cause of cessation was registered as both
treatment failure and AE; for these patients, the cause of with-
drawal was subsequently classified as an AE. Patients stop-
ping treatment prior to surgery were considered to remain on
therapy if the duration of the pause did not exceed 12 months.
For study of the impact of concomitant DMARDs, the patients
were divided into six groups. Two main groups of patients
received etanercept or infliximab. These groups were further
subdivided into three groups depending on concomitant
DMARD use at TNF-blocking treatment initiation: one group of
patients receiving MTX, another group of patients receiving
Figure 1
Number of patients starting anti-tumour necrosis factor (TNF) therapy  during the observational period Number of patients starting anti-tumour necrosis factor (TNF) therapy 
during the observational period. The figure presents the number of 
rheumatoid arthritis patients, per quarter, starting infliximab, etanercept, 
or adalimumab for the first time during the period of 1999 through 
2004 in southern Sweden.Available online http://arthritis-research.com/content/8/6/R174
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other DMARDs, and finally a group of patients treated with
TNF blockers as the only antirheumatic therapy (mono-
therapy). The group 'other DMARD' consisted of patients
receiving hydroxychloroquine, sulfasalazine, and (to a lesser
extent) leflunomide and azathioprine.
In an open study design, there is a possibility for selection bias
favouring one drug over another. Therefore, a subgroup analy-
sis was performed including patients from 1999 through June
2001 with a follow-up time of 2 years (until June 2003).
Because of limited access of TNF-blocking drugs during this
period (Figure 1), analyses of treatments were possible with-
out selection bias as well as during a 2-year observational
period with restricted access of TNF-blocking agents. After
June 2003, infliximab, etanercept, as well as adalimumab were
widely available (Figure 1). The number of biologic-naïve
patients starting adalimumab was too limited to allow mean-
ingful analysis, and patients treated with adalimumab were
therefore excluded from this report.
Furthermore, a linkage between the SSATG database and the
Swedish in-hospital discharge register was performed to iden-
tify possible differences in co-morbidities at treatment initiation
for the infliximab and the etanercept groups. Patients initiating
therapy were checked for an up-to-10-year prior history of car-
diovascular diseases, any malignancies, chronic pulmonary
diseases, and diabetes according to ICD (International Statis-
tical Classification of Diseases and Related Health Problems)
9 or 10 diagnosis codes. Ethical approval was obtained before
making the register linkage.
To minimise follow-up loss, data for all patients included were
checked every 6 months. In case of incomplete clinical data for
a period of more than 250 days, a request to report the miss-
ing data or provide the time and reason for potential drug dis-
continuation was sent to the treating physician. Less than 2%
of the patients remained with unknown treatment status when
we retrieved results for this study.
Statistical analysis
Baseline clinical characteristics were analysed by the Kruskal-
Wallis and Mann-Whitney U tests for comparison of groups for
continuous variables, whereas the χ2 test was used for cate-
gorical variables. Values are reported as the mean ± standard
deviation except where stated otherwise. Adherence to ther-
apy data was estimated according to Kaplan-Meier and further
analysed with log-rank statistics for comparing different treat-
ments. Cox proportional hazard models were used to investi-
gate the effect of possible risk factors for treatment
termination (age, gender, disease duration, HAQ score,
DAS28, CRP level, number of previous DMARDs, year of
treatment initiation, and concomitant DMARDs). These mod-
els were based on all patients included in the study except
where stated otherwise. Moreover, time-dependent Cox pro-
portional hazard models were performed using covariates that
might change over time (HAQ score, CRP level, and DAS28)
to complement findings from the predictor analysis. The model
assumptions for using these regression analyses were tested
and found valid. Level of significance was chosen to be p <
0.05.
Results
Baseline data
During the observational period, a total of 1,161 patients were
enrolled in the study. Demographic data and clinical character-
istics of patients studied are summarised in Table 1. Notably,
only two significant differences were found when comparing
the respective subgroups of infliximab and etanercept.
Patients receiving infliximab as monotherapy were older than
patients receiving etanercept as monotherapy. Patients
treated with concomitant MTX received a significantly lower
weekly dose when treated with infliximab compared with
etanercept (14.3 mg/week versus 16.1 mg/week).
When comparing baseline data for the different subgroups
(concomitant MTX, other DMARD combination, or TNF-block-
ing agent as monotherapy), several significant differences
were found. In general, patients receiving concomitant MTX
had lower HAQ, VASglobal, VASpain, and DAS28 scores
when compared with other subgroups. Patients in the MTX
groups were overall younger, had shorter disease duration,
and fewer previous DMARDs. Finally, patients receiving other
DMARDs or TNF blockers as monotherapy had a trend for
higher CRP levels. Thus, the main differences in baseline char-
acteristics were found between subgroups of patients and not
between patients receiving infliximab or etanercept.
The register linkage did not show any significant differences in
discharge diagnosis for patients initiated on infliximab com-
pared with etanercept. Thus, patients eligible for therapy had
a 10-year prior hospitalisation history of cardiovascular dis-
ease in 7% versus 6%, diabetes in 5% versus 5%, any malig-
nancies in 4% versus 3%, and chronic pulmonary disease in
4% versus 4% for infliximab- and etanercept-treated patients,
respectively.
Levels of adherence to therapy for infliximab and etanercept
with concomitant MTX at 5-year (4-year; 1-year) follow-up
were 36% (38%; 69%) and 65% (75%; 89%), respectively.
When infliximab and etanercept were administered as mono-
therapy, the levels of adherence to therapy at 4 years (1 year)
were 18% (47%) and 53% (74%), respectively. The corre-
sponding numbers for TNF blockers given in combination with
other DMARDs were 27% (58%) and 71% (85%) for inflixi-
mab and etanercept, respectively.
Levels of total adherence to therapy for all subgroups are
shown in Figures 2 to 3a, whereas survival curves for with-
drawal from treatment due to AEs and treatment failure are
shown in Figures 2 to 3b and 2 to 3c, respectively. InfliximabArthritis Research & Therapy    Vol 8 No 6    Kristensen et al.
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showed significantly lower total adherence to therapy com-
pared with etanercept for all subgroups (p < 0.001).
Figures 2 to 3b show that infliximab has more withdrawals
because of AEs when compared with etanercept in all three
subgroups (p < 0.001). However, when studying withdrawals
due to treatment failure (Figures 2 to 3c), the differences
between infliximab and etanercept were less obvious and only
significant for the subgroups of patients receiving MTX (p =
0.026) and monotherapy (p = 0.002). Thus, AEs are mainly
what account for the differences seen in total adherence to
therapy between etanercept and infliximab.
Patients receiving concomitant MTX showed significantly
higher levels of total adherence to therapy when compared
with monotherapy both in the infliximab and the etanercept
groups (p < 0.001). Also, patients treated with infliximab expe-
rienced significantly better adherence to therapy when treated
with MTX (p  = 0.002) compared with other concomitant
DMARDs. No such difference was found for etanercept. In the
etanercept group, total adherence to therapy was significantly
higher for the subgroup receiving concomitant DMARDs com-
pared with monotherapy (p = 0.015).
Patients receiving MTX had fewer dropouts due to AEs when
compared with patients receiving biologic therapy as mono-
therapy (p < 0.001). Also, patients receiving infliximab with
concomitant MTX showed fewer withdrawals because of AEs
when compared with patients receiving other concomitant
DMARDs (p  < 0.001). No such difference was found for
patients receiving etanercept. When the impact of DMARDs
on withdrawal due to treatment failure was studied, patients in
the infliximab group receiving monotherapy had higher with-
drawal compared with patients receiving MTX (p = 0.019) or
Table 1
Demographic and clinical characteristics at baseline
Infliximab I Etanercept II Level of significance
MTX A Other DMARD B Mono-therapy C MTX A Other DMARD B Mono-therapy C
Number 501 116 104 179 68 193
Age (years) 55.0 (13.6) 57.4 (12.0) 61.0 (12.1) 53.4 (12.9) 54.0 (12.4) 57.7 (13.0) IC vs. IIC, p = 0.040
IIA vs. IIC, p = 0.003
IA vs. IC, p < 0.001
IB vs. IC, p = 0.027
Female 74% 75% 78% 78% 84% 84%
Disease duration (months) 133.5 (113.8) 165.4 (118.5) 192.9 (132.4) 132.8 (107.3) 180.1 (115.1) 185.3 (121.4) IIA vs. IIC, p < 0.001
IIA vs. IIB, p < 0.001
IA vs. IB, p = 0.002
IA vs. IC, p < 0.001
HAQ score 1.34 (0.62) 1.57 (0.58) 1.69 (0.58) 1.30 (0.61) 1.61 (0.58) 1.60 (0.65) IIA vs. IIB, p < 0.001
IIA vs. IIC, p < 0.001
IA vs. IB, p < 0.001
IA vs. IC, p < 0.001
DAS28 5.5 (1.2) 5.8 (1.1) 5.7 (1.2) 5.5 (1.0) 5.8 (1.2) 5.9 (1.1) IIA vs. IIB, p = 0.026
IIA vs. IIC, p < 0.001
IA vs. IB, p = 0.013
Number of previous DMARDs 3.1 (1.7) 4.2 (2.2) 4.2 (1.9) 3.1 (1.1) 4.2 (1.8) 4.5 (2.1) IIA vs. IIB, p < 0.001
IIA vs. IIC, p < 0.001
IA vs. IB, p < 0.001
IA vs. IC, p < 0.001
VASglobal (mm) 60 (22) 70 (18) 67 (22) 60 (22) 71 (17) 66 (21) IIA vs. IIB, p = 0.001
IIA vs. IIC, p = 0.017
IA vs. IB, p < 0.001
IA vs. IC, p = 0.004
VASpain (mm) 60 (23) 70 (17) 64 (24) 60 (22) 66 (19) 65 (22) IIA vs. IIC, p = 0.020
IA vs. IB, p < 0.001
EVALglobal (mm) 57 (23) 57 (22) 58 (23) 56 (24) 56 (21) 60 (24) IIA vs. IIC, p = 0.015
MTX dosage (mg/week) 14.3 (6.0) - - 16.1 (5.0) - - IA vs. IIA, p < 0.001
CRP (mg/litre) 33.1 (34.0) 39.5 (38.7) 39.1 (36.6) 32.1 (34.5) 38.4 (30.0) 41.6 (38.0) IIA vs. IIB, p = 0.029
IIA vs. IIC, p = 0.008
ESR (mm/hour) 35.0 (24.1) 42.1 (26.8) 44.0 (28.2) 34.2 (23.1) 41.9 (25.0) 44.4 (27.1)
Values are presented as the mean (standard deviation). CRP, C-reactive protein; DAS28, 28-joint disease activity score; DMARD, disease-
modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EVALglobal, physician's global assessment of disease activity on a five-grade 
scale; HAQ, health assessment questionnaire; MTX, methotrexate; VASglobal, visual analogue scale for general health; VASpain, visual analogue 
scale for pain.Available online http://arthritis-research.com/content/8/6/R174
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other concomitant DMARDs (p = 0.011). Patients receiving
etanercept did not show these differences.
There were no differences at treatment termination in disease
activity, measured by DAS28, between patients terminating
treatment because of failure in the infliximab groups (DAS28
= 5.1 [95% confidence interval (CI) 4.9; 5.4]) compared with
the etanercept groups (DAS28 = 5.1 [95% CI 4.8; 5.4]).
Patients withdrawing from treatment because of miscellane-
ous reasons comprised only a small percentage of all with-
Figure 2
Adherence to therapy for patients treated with etanercept Adherence to therapy for patients treated with etanercept. The level of adherence to therapy is shown as the fraction (between 1 and 0) of patients 
remaining on therapy during the observation period. Withdrawal due to any reason (a), adverse events (b), or failure to treatment (c) is presented 
separately. The number of patients under observation at each time point is listed at the bottom of the figure. DMARD, disease-modifying antirheu-
matic drug.Arthritis Research & Therapy    Vol 8 No 6    Kristensen et al.
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drawals, and no statistical dissimilarities were found between
the different treatment groups (data not shown).
Regression analysis
Significant differences in baseline characteristics between
subgroups (Table 1) made it necessary to perform a Cox pro-
portional hazard regression analysis to elucidate whether
Figure 3
Adherence to therapy for patients treated with infliximab Adherence to therapy for patients treated with infliximab. The level of adherence to therapy is shown as the fraction (between 1 and 0) of patients 
remaining on therapy during the observation period. Withdrawal due to any reason (a), adverse events (b), or failure to treatment (c) is presented 
separately. The number of patients under observation at each time point is listed at the bottom of the figure. DMARD, disease-modifying antirheu-
matic drug.Available online http://arthritis-research.com/content/8/6/R174
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these differences influenced adherence to therapy. Table 2
shows hazard ratios (HRs) and 95% CIs for the regression
analysis. When differences in baseline data were adjusted for,
MTX was shown to protect against premature treatment termi-
nation when compared with other concomitant DMARDs and
monotherapy. Also, all patients treated with infliximab had a
threefold increased risk of stopping therapy when compared
with etanercept. Furthermore, using HAQ score, CRP level,
and DAS28 as time-dependent covariates showed similar
findings with only minor decrements in differences described
above (Table 2). The reason for better overall adherence to
therapy with concomitant MTX appeared to be significantly
fewer dropouts because of AEs (p < 0.001). On the other
hand, MTX did not show significant differences compared with
other DMARDs and monotherapy when examining dropouts
because of treatment failure. No significant statistical interac-
tion was found between subgroup treatment and TNF-block-
ing agents with regard to level of total adherence to therapy
(that is, the differences found between drug survival of inflixi-
mab compared with etanercept did not depend on concomi-
tant DMARD treatment).
Subgroup analysis of etanercept and infliximab comparing
groups of patients starting either TNF-blocking drugs in com-
bination with MTX or as monotherapy is shown in Table 3. The
number of patients initiated on TNF-blocking agents in combi-
nation with other DMARDs was too small to allow meaningful
subgroup analysis. No significant baseline differences were
found when comparing the respective subgroups of infliximab
and etanercept for age, gender, DAS28, CRP level, disease
duration, and HAQ score (data not shown). The two inclusion
periods displayed in Table 3 demonstrate that either infliximab
or etanercept was limited in access, thus allowing for treat-
ment initiation of either drug without selection bias. The 1-year
level of adherence to therapy in this subgroup was similar to
the complete adherence analysis, and when adjusting for age,
gender, DAS28, HAQ score, disease duration, previous
DMARDs, and CRP level, patients treated with infliximab had
a threefold to fourfold increased risk for stopping therapy com-
pared with etanercept (p  < 0.001). The HRs diminished
slightly to 2.75 and 3.15 (p < 0.001) when using HAQ score,
CRP level, and DAS28 as time-dependent covariates (Table
3). These relative risks were consistent with the results
reported for the entire group of patients. The Cox proportional
Table 2
Hazard ratios with 95% confidence intervals and levels of significance for stopping treatment
All reasons HR (95% CI) Level of significance
Unadjusted infliximab vs. etanercept 2.37 (1.91; 2.93) p < 0.001
aInfliximab vs. etanercept 2.92 (2.32; 3.69) p < 0.001
bMonotherapy vs. MTX 1.82 (1.45; 2.29) p < 0.001
bOther DMARD vs. MTX 1.45 (1.12; 1.87) p < 0.010
bMonotherapy vs. other DMARD 1.22 (0.94; 1.61) p = 0.127
All reasons, time-dependent Cox regression analysis HR (95% CI) Level of significance
aInfliximab vs. etanercept 2.83 (2.27; 3.54) p < 0.001
bMonotherapy vs. MTX 1.48 (1.19; 1.85) p < 0.001
bOther DMARD vs. MTX 1.33 (1.08; 1.55) p = 0.017
bMonotherapy vs. other DMARD 1.10 (0.86; 1.40) p = 0.448
Adverse events HR (95% CI) Level of significance
bMonotherapy vs. MTX 2.14 (1.61; 2.84) p < 0.001
bOther DMARD vs. MTX 1.75 (1.28; 2.04) p = 0.001
bMonotherapy vs. other DMARD 1.23 (0.88; 1.71) p = 0.231
Treatment failure HR (95% CI) Level of significance
bMonotherapy vs. MTX 1.31 (0.86; 1.99) p = 0.215
bOther DMARD vs. MTX 1.07 (0.66; 1.73) p = 0.782
bMonotherapy vs. other DMARD 1.22 (0.72; 2.06) p = 0.454
aAlso adjusted for differences in concomitant disease-modifying antirheumatic drugs (DMARDs). bAlso adjusted for differences in tumour necrosis 
factor-blocking treatment. The first row contains unadjusted data, whereas the remaining data were adjusted for differences in age, gender, year of 
treatment initiation, 28-joint disease activity score (DAS28), health assessment questionnaire (HAQ) score, disease duration, previous DMARDs, 
and C-reactive protein (CRP) level. Data presented in the second section use HAQ score, DAS28, and CRP level as time-dependent covariates. 
CI, confidence interval; HR, hazard ratio; MTX, methotrexate.Arthritis Research & Therapy    Vol 8 No 6    Kristensen et al.
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hazard models used in the subgroup analysis were based only
on patients included during the period of interest.
Predictors for drug discontinuation
Independent of anti-TNF treatment, significant predictors of
premature treatment termination were higher age (HR = 1.11;
CI = 1.01; 1.22), higher HAQ score (HR = 1.17; CI = 1.06;
1.30), and higher previous number of DMARDs at inclusion
(HR = 1.13; CI = 1.02; 1.25). In contrast, high CRP level at
treatment initiation was a predictor for prolonged drug adher-
ence (HR = 0.90; CI = 0.81; 0.98). Gender, year of treatment
initiation, DAS28, and disease duration prior to treatment initi-
ation did not predict the level of adherence to therapy.
Discussion
The results presented in this study demonstrate a higher level
of adherence to therapy for etanercept compared with inflixi-
mab. This difference was significant for patients treated with
concomitant MTX, other concomitant DMARDs, as well as for
patients treated with TNF-blocking drugs only. Adjusting for
potential confounding factors further accentuated the differ-
ence. This result is in agreement with data recently presented
by Gomez-Reino and coworkers [14]. However, information
on concomitant DMARDs, HAQ scores, and disease activity
was not available in the study by Gomez-Reino and coworkers,
making direct comparison of absolute HRs and levels of
adherence to therapy difficult.
The levels of adherence to therapy found in this study are
somewhat higher than data recently presented by Zink and
coworkers [10]. One explanation for this could be that our
material includes only patients receiving their first treatment
course of biologic therapy whereas the adherence data pre-
sented by Zink and coworkers also includes patients previ-
ously treated with other biological therapy. In addition, CRP
levels in patients enrolled in our study were considerably
higher than in patients studied by Zink and coworkers (30 to
41 mg/l compared with 20 mg/l), and as shown in this paper,
high CRP levels might be a predictor for a high level of adher-
ence to therapy. On the other hand, the 1-year level of adher-
ence to therapy found in our study closely resembles values
found in randomised controlled clinical trials. We found 1-year
level of adherence to therapy for patients treated with inflixi-
mab and concomitant MTX to be approximately 70% com-
pared with 73% in the ATTRACT (Anti-TNF Trial in
Rheumatoid Arthritis with Concomitant Therapy) trial [2]. Also,
patients treated with etanercept showed a 74% 1-year level of
adherence to therapy compared with 76% in the TEMPO (Trial
of Etanercept and Methotrexate with Radiographic Patient
Outcomes) trial when given as monotherapy [9]. When etaner-
cept was given in combination with MTX, the corresponding
numbers were 89% compared with 84%. However, great
methodological differences exist between RCTs and observa-
tional studies, making direct comparisons difficult to interpret
[15].
In accordance with previous studies, we found that patients
treated with concomitant MTX experienced a higher
adherence to therapy [8,10] compared with patients treated
with anti-TNF agents only. Moreover, our data suggest that
MTX is superior to concomitant DMARDs such as hydroxy-
chloroquine, sulfasalazine, and leflunomide in preventing treat-
ment discontinuation of TNF blockers. This difference was less
clear for patients treated with etanercept when examining
unadjusted adherence data in Figure 2a. However, when
adjusting for heterogeneity at baseline, a difference was found
(Table 2). A possible explanation for the apparent superiority
of concomitant MTX may be that MTX is a more potent
antirheumatic drug in itself. Another reason could be that
patients not tolerating MTX also possess yet-undefined char-
acteristics or co-morbidities predisposing to lower levels of
adherence to anti-TNF therapy. Nevertheless, our data sug-
gest that patients who tolerate MTX well also are likely to tol-
erate TNF-blocking agents. Thus, tolerance to MTX therapy
may be used as a surrogate measure for potential high tolera-
bility of anti-TNF treatments in clinical practice.
Table 3
Number of patients in subgroup analysis, adherence to therapy, and hazard ratios for stopping treatment
Patients included 
February through 
December 1999
Patients included 
February 2000 through 
June 2001
Adherence to therapy 
after 1 year (2 years)
Hazard ratio (95% CI) Hazard ratio (95% CI), time-
dependent Cox regression 
analysis
Etanercept and MTX 58 5a 90% (87%) 3.27 (1.76; 6.08) 3.15 (1.84; 5.39)
Infliximab and MTX 12a 206 68% (60%)
Etanercept as 
monotherapy
100 13a 77% (69%) 4.26 (2.60; 7.00) 2.75 (1.70; 4.46)
Infliximab as 
monotherapy
0a 56 45% (27%)
aPatients not included in analysis. The hazard ratios were adjusted for differences in age, gender, 28-joint disease activity score (DAS28), health 
assessment questionnaire (HAQ) score, disease duration, previous disease-modifying antirheumatic drugs, and C-reactive protein (CRP) level. 
Data presented in the last column use HAQ score, DAS28, and CRP level as time-dependent covariates. For details, see Results. CI, confidence 
interval; MTX, methotrexate.Available online http://arthritis-research.com/content/8/6/R174
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Our study identifies withdrawal due to AEs as the main cause
of differences in total adherence to therapy between infliximab
and etanercept. In addition, the positive impact of concomitant
MTX was also associated primarily with fewer dropouts
because of AEs. One mechanism underlying this difference
could be the formation of neutralising and immunopathogenic
antibodies against the murine part of infliximab, leading to a
higher number of AEs [16]. It can also be speculated that MTX
in turn can effectively inhibit the formation of these immun-
opathogenic antibodies, thus decreasing the risk for AEs [16-
18]. Moreover, various data regarding differences in mecha-
nism of action between infliximab and etanercept are emerging
[19-21]. These findings could possibly explain differences
demonstrated in this study.
At this point, it should be noted that reasons for ceasing treat-
ment are scored by the treating physician, and inter-observer
variation in the classification of the stop reason therefore
exists. The reason for the low percentages of termination
because of both treatment failure and AEs is due primarily to
the design of the registration scheme and should not be inter-
preted as certainty of the termination reason. Thus, results
regarding cause of treatment termination must be interpreted
with care, placing more emphasis on overall adherence to
therapy [10]. Although potential bias also exists when using
this measure in drug studies [22], the wide use of this prag-
matic measure makes it suitable for this report and further
inter-trial comparisons.
We identify high age, elevated HAQ score, and higher previ-
ous number of DMARDs as significant predictors of premature
treatment termination. In contrast, high CRP level at inclusion
seemed to protect against treatment termination.
Patients with a high level of systemic inflammation may have a
larger potential for improvement in clinical status when an
immunosuppressive drug such as a TNF-blocking agent is
administered. This may explain the better drug adherence
observed in patients with high CRP level at inclusion.
The open non-randomised nature of this study may induce bias
in the process of selecting patients for particular treatments
and the subsequent collection of data [23-25]. All data entries
were centralised to ensure uniform interpretation of registra-
tion forms. Confounding by indication cannot be excluded
from this study. Consequently, a Cox regression model was
applied to adjust for differences in baseline. This adjustment
increased the HR for terminating treatment of infliximab com-
pared with etanercept from 2.37 to 2.92 (Table 2), indicating
that potential selection bias might have favoured prescription
of infliximab over etanercept. Consistently, the findings were
supported by time-dependent Cox proportional hazard models
using covariates that might change over time (HAQ score,
CRP level, and DAS28). Moreover, a subgroup analysis was
performed comparing unselected treatment initiation of
etanercept and infliximab (Table 3). The result of this analysis
was consistent with the overall survival analysis both in relation
to absolute adherence values and HRs. Thus, the subgroup
analysis showed that the risk for terminating treatment with inf-
liximab was threefold to fourfold higher than for etanercept. It
is therefore unlikely that selection bias has had substantial
impact on the results presented in this study. Moreover, only
minor differences were found between the main therapies at
baseline, making selection bias less likely. Also, linkage to in-
hospital discharge register showed no baseline difference in
prior diabetes, malignancies, chronic pulmonary diseases, and
cardiovascular diseases when comparing patients treated
with etanercept with those receiving infliximab. Patients enter-
ing the subgroup analysis were followed only until June 2003.
During this period, the availability of TNF-blocking drugs was
limited (Figure 1), and switching of therapy because of con-
venience was therefore minimised.
The National Healthcare System in Sweden provides free
access to TNF-blocking drugs if prescribed by the treating
physician, regardless of the social status of the patient. Thus,
potential differences in costs of the TNF-blocking agents did
not induce a selection bias.
Also, the possibility for termination bias was investigated by
examining disease activity of patients terminating therapy
because of treatment failure. We did not find any differences
in the level of disease activity when comparing infliximab with
etanercept, and bias in the withdrawal of patients because of
treatment failure is therefore unlikely. Finally, at present there
are only sparse data directly comparing the different biologic
drugs [25], thus giving no obvious reason for favouring pre-
scription of one drug over another.
Conclusion
This study indicates that treatment with etanercept leads to
higher adherence to therapy than treatment with infliximab.
Concomitant MTX is associated with improved treatment con-
tinuation of biologics when compared with both TNF blockers
as monotherapy and TNF blockers combined with other
DMARDs. Thus, our data suggest that patients eligible for
TNF-blocking treatment have a better chance of long adher-
ence to therapy if they are tolerating MTX and started on
etanercept rather than infliximab. Treating patients with low
CRP levels, high age, elevated HAQ score, and high previous
number of DMARDs may lead to premature treatment
termination.
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